Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

5 treatments under study, led by Losartan

Related Conditions

Often studied with 8 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results50% success

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Recruiting1
Active Not Recruiting1
Completed1
Terminated1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT00084305Active Not Recruiting

Analysis of Specimens From Individuals With Pulmonary Fibrosis

NCT00001456RecruitingPrimary

Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome

NCT01417520Completed

Clinical and Pathophysiological Investigations Into Erdheim Chester Disease

NCT00467831Phase 1/2TerminatedPrimary

Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome

Showing all 4 trials

Research Network

Common Treatments

  • Losartan1
  • Pravastatin1
  • Acetylcysteine1
  • Erythromycin1
  • Zileuton1

Active Sponsors

  • National Human Genome Research Institute (NHGRI)4

Top Investigators

Related Conditions

  • Pulmonary Fibrosis3
  • Healthy Volunteers1
  • Platelet Storage Pool Deficiency1
  • Metabolic Disease1
  • Cancer1

Activity Timeline